Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial
3 months ago
53
With fenebrutinib, the institution aims to motorboat a caller oral attraction for aggregate sclerosis that offers some greater convenience to patients comparative to Ocrevus.
3 months ago
53
.png)
